VolitionRx Limited (NYSE AMERICAN: VNRX) launched an online webshop to sell recombinant nucleosomes developed over the past 10 years, according to a company announcement.

The rNuQ webshop offers nucleosomes manufactured in an ISO 13485 certified facility and stored at +4 °C in a glycerol-free buffer. The products include nucleosomes with various histone compositions, post-translational modifications, and citrullination patterns.

"We are delighted to launch our extensive range of off-the-shelf recombinant nucleosomes through this easy-to-use website," said Dr. Jasmine Kway, Chief Executive Officer of Singapore Volition. "This is a further expansion of our Nu.Q Discover pillar, where we are now serving close to 100 clients worldwide, including many top pharma and diagnostic companies."

The product range includes H3K18lactylations nucleosomes, which the company states are not available from other suppliers. Researchers can select nucleosomes based on specific experimental requirements.

VolitionRx reported 86% revenue growth for Nu.Q Discover in 2025 and anticipates similar growth in 2026. The company serves pharmaceutical and diagnostic companies, with some clients progressing to late-stage clinical trials using Volition's assays as pharmacodynamic biomarkers.

The Henderson, Nevada-based epigenetics company is also discussing bespoke assay development with pharmaceutical companies for biospecimens beyond blood plasma.

VolitionRx develops blood tests for disease detection and monitoring, including some cancers and diseases associated with NETosis. The company operates research facilities in Belgium, the United States, and London.